Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
236 studies found for:    Open Studies | "Macular Degeneration"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Macular Degeneration"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye
Condition: Macular Degeneration
Intervention: Drug: Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)
2 Recruiting Five-year Incidence of Age-related Macular Degeneration in the Central Region of Portugal
Condition: Age-Related Macular Degeneration
Intervention:
3 Recruiting A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration
Condition: Age-Related Macular Degeneration
Intervention: Drug: DE-122
4 Not yet recruiting Evaluation of Visual Function and Driving Health Using Ocusweep in Patients Suffering From Wet Age-related Macular Degeneration
Condition: Macular Degeneration
Intervention: Device: Ocusweep system
5 Recruiting Intravitreal Aflibercept in Wet Age Related Macular Degeneration Patients With an Incomplete Response to Routine Ranibizumab Injections
Condition: Age Related Macular Degeneration
Intervention: Drug: Aflibercept
6 Recruiting Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
Condition: Macular Degeneration
Intervention: Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
7 Recruiting Proton Radiation Therapy for Macular Degeneration
Condition: Age-Related Macular Degeneration
Intervention: Radiation: Proton radiation
8 Recruiting Study of Dark Adaptation in Age-Related Macular Degeneration
Condition: Age-Related Macular Degeneration
Intervention:
9 Recruiting Evaluation the Pharmacokinetics, Safety, Tolerability of TK001 in Patients With Neovascular Age-related Macular Degeneration
Condition: Neovascular Age-related Macular Degeneration
Intervention: Biological: TK001
10 Recruiting OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab
Condition: Wet Macular Degeneration
Interventions: Drug: Ranibizumab;   Drug: OZURDEX
11 Recruiting Study of DS-7080a for the Treatment of Neovascular Age-Related Macular Degeneration
Condition: Neovascular Age-Related Macular Degeneration
Interventions: Drug: DS-7080a;   Drug: Ranibizumab
12 Recruiting A Pharmacokinetic Study of Intravitreal Aflibercept Injection in Vitrectomized and Non-vitrectomized Eyes With Wet Age-related Macular Degeneration (DRAW).
Condition: Neovascular Macular Degeneration
Intervention: Drug: Aflibercept
13 Recruiting Clinical Study of Subretinal Transplantation of Human Embryo Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Macular Degeneration Diseases
Conditions: Macular Degeneration;   Stargardt's Macular Dystrophy
Intervention: Procedure: Subretinal transplantation
14 Recruiting Safety and Efficacy of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration
Condition: Macular Degeneration
Interventions: Drug: abicipar pegol;   Drug: ranibizumab;   Other: sham procedure
15 Recruiting A Safety and Efficacy Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration
Condition: Macular Degeneration
Interventions: Drug: abicipar pegol;   Drug: ranibizumab;   Other: sham procedure
16 Recruiting Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Participants With Subfoveal Neovascular Age-Related Macular Degeneration (LADDER)
Condition: Macular Degeneration
Interventions: Drug: Ranibizumab ITV injection;   Drug: Ranibizumab through RPDS Implant
17 Recruiting Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration
Condition: Age-related Macular Degeneration
Intervention: Drug: Ranibizumab 0.5mg
18 Recruiting To Describe the Use of Intravitreal Aflibercept and to Describe Follow-up as Well as Treatment Patterns in Patients With Wet Age-related Macular Degeneration (wAMD) or Diabetic Macular Edema (DME) in Routine Clinical Practice in Canada.
Condition: Wet Macular Degeneration
Intervention: Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
19 Recruiting Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular Degeneration
Condition: Wet Macular Degeneration
Intervention: Drug: Lucentis
20 Recruiting Microperimetry and Eye Progressing From Stage 3 to Stage 4 Age-related Macular Degeneration (AMD)
Condition: Stage 3 Age Related Macular Degeneration (AREDS Classification)
Intervention: Device: MAIA™ (Centrevue, Padova, Italy; distributed in France by EDC Lamy, Carvin, France)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.